309 related articles for article (PubMed ID: 9042196)
1. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
Nishio K; Ishida T; Arioka H; Kurokawa H; Fukuoka K; Nomoto T; Fukumoto H; Yokote H; Saijo N
Anticancer Res; 1996; 16(6B):3387-95. PubMed ID: 9042196
[TBL] [Abstract][Full Text] [Related]
2. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression.
Kitagawa M; Higashi H; Takahashi IS; Okabe T; Ogino H; Taya Y; Hishimura S; Okuyama A
Oncogene; 1994 Sep; 9(9):2549-57. PubMed ID: 8058318
[TBL] [Abstract][Full Text] [Related]
3. [Effect of cisplatin on cell cycle regulators].
Nishio K; Saijo N
Gan To Kagaku Ryoho; 1994 Feb; 21(3):289-94. PubMed ID: 8109984
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
5. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.
Hsu TS; Chen C; Lee PT; Chiu SJ; Liu HF; Tsai CC; Chao JI
Cancer Chemother Pharmacol; 2008 Oct; 62(5):799-808. PubMed ID: 18193228
[TBL] [Abstract][Full Text] [Related]
6. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells.
Yin F; Giuliano AE; Law RE; Van Herle AJ
Anticancer Res; 2001; 21(1A):413-20. PubMed ID: 11299771
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
8. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.
Roberson RS; Kussick SJ; Vallieres E; Chen SY; Wu DY
Cancer Res; 2005 Apr; 65(7):2795-803. PubMed ID: 15805280
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
10. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
[TBL] [Abstract][Full Text] [Related]
11. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase.
Kitagawa M; Okabe T; Ogino H; Matsumoto H; Suzuki-Takahashi I; Kokubo T; Higashi H; Saitoh S; Taya Y; Yasuda H
Oncogene; 1993 Sep; 8(9):2425-32. PubMed ID: 8395680
[TBL] [Abstract][Full Text] [Related]
12. [Cell cycle regulation by anticancer agent].
Nomoto T; Nishio K; Saijo N
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1719-23. PubMed ID: 7574801
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
14. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells.
Poon RY; Chau MS; Yamashita K; Hunter T
Cancer Res; 1997 Nov; 57(22):5168-78. PubMed ID: 9371520
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity.
Arita Y; Buffolino P; Coppock DL
Exp Cell Res; 1998 Aug; 242(2):381-90. PubMed ID: 9683525
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts.
Someya A; Tanaka N; Okuyama A
Biochem Biophys Res Commun; 1994 Jan; 198(2):536-45. PubMed ID: 8297363
[TBL] [Abstract][Full Text] [Related]
17. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
Funayama Y; Nishio K; Takeda Y; Kubota N; Ohira T; Ohmori T; Ohta S; Ogasawara H; Hasegawa S; Saijo N
Anticancer Res; 1993; 13(6A):1981-8. PubMed ID: 8297104
[TBL] [Abstract][Full Text] [Related]
18. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
